GTBP Total Current Assets vs Current Deferred Revenue Analysis
GTBP Stock | USD 2.80 0.24 7.89% |
GT Biopharma financial indicator trend analysis is much more than just examining GT Biopharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GT Biopharma is a good investment. Please check the relationship between GT Biopharma Total Current Assets and its Current Deferred Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
Total Current Assets vs Current Deferred Revenue
Total Current Assets vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GT Biopharma Total Current Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between GT Biopharma's Total Current Assets and Current Deferred Revenue is -0.38. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of GT Biopharma, assuming nothing else is changed. The correlation between historical values of GT Biopharma's Total Current Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of GT Biopharma are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Current Assets i.e., GT Biopharma's Total Current Assets and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | -0.38 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from GT Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Selling General Administrative is relatively stable compared to the past year. As of 12/11/2024, Issuance Of Capital Stock is likely to grow to about 10.2 M, while Sales General And Administrative To Revenue is likely to drop 2.17.
2023 | 2024 (projected) | Total Operating Expenses | 13.6M | 10.7M | Cost Of Revenue | 3.6K | 3.4K |
GT Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
GT Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GT Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 396K | 5.7M | 32.2M | 16.7M | 14.1M | 13.2M | |
Other Current Liab | 4.4M | 6.5M | 2.0M | 1.6M | 2.2M | 2.6M | |
Total Current Liabilities | 19.7M | 35.1M | 10.3M | 4.9M | 6.6M | 6.9M | |
Total Stockholder Equity | (19.1M) | (29.3M) | 21.9M | 11.7M | 7.5M | 7.1M | |
Property Plant And Equipment Net | 35K | 110K | 0.0 | 165K | 53K | 50.4K | |
Net Debt | 13.3M | 21.0M | (8.9M) | (5.5M) | (1.0M) | (970.0K) | |
Retained Earnings | (567.3M) | (595.6M) | (653.6M) | (674.5M) | (682.1M) | (648.0M) | |
Accounts Payable | 1.9M | 2.2M | 8.2M | 3.1M | 4.3M | 4.5M | |
Cash | 28K | 5.3M | 9.0M | 5.7M | 1.1M | 1.2M | |
Non Current Assets Total | 25.3M | 122K | 0.0 | 174K | 53K | 50.4K | |
Cash And Short Term Investments | 28K | 5.3M | 32.0M | 16.5M | 14.0M | 14.7M | |
Common Stock Total Equity | 50K | 51K | 70K | 52K | 46.8K | 44.5K | |
Common Stock Shares Outstanding | 112.8K | 146.2K | 938.5K | 1.1M | 1.3M | 1.3M | |
Liabilities And Stockholders Equity | 396K | 5.7M | 32.2M | 16.7M | 14.1M | 13.2M | |
Other Current Assets | 246K | 364K | 190K | 54K | 84K | 79.8K | |
Other Stockholder Equity | 548.1M | 566.4M | 673.2M | 686.2M | 689.5M | 724.0M | |
Total Liab | 19.7M | 35.1M | 10.3M | 5.0M | 6.6M | 7.1M | |
Property Plant And Equipment Gross | 35K | 110K | 0.0 | 165K | 53K | 50.4K | |
Total Current Assets | 274K | 5.7M | 32.2M | 16.6M | 14.1M | 14.8M | |
Common Stock | 70K | 52K | 1.1M | 33K | 1K | 950.0 | |
Short Long Term Debt Total | 10.8M | 13.4M | 26.3M | 174K | 58K | 55.1K | |
Short Term Debt | 10.8M | 13.4M | 26.3M | 220K | 116K | 110.2K | |
Net Tangible Assets | (13.7M) | (19.1M) | (29.3M) | 21.9M | 25.2M | 26.5M | |
Short Long Term Debt | 31K | 10.8M | 13.2M | 26.3M | 35.7K | 33.9K | |
Net Invested Capital | (5.9M) | (2.9M) | 21.9M | 11.7M | 7.5M | 7.1M | |
Net Working Capital | (19.4M) | (29.4M) | 21.9M | 11.6M | 7.4M | 7.8M | |
Capital Stock | 73K | 55K | 1.1M | 34K | 2K | 1.9K |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.74 | LLY | Eli Lilly | PairCorr |
0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.51 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.